FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
RUBY Financial Statements
Year
2022
2021
2020
2019
CF from Operating Activities
-150.14M
-145.12M
-127.65M
-110.44M
Net Income
-179.67M
-196.55M
-167.73M
-163.46M
Depreciation & Amortization
6.25M
7.72M
5.69M
3M
Deferred Income Taxes
0
118k
266k
-1.99M
Stock Based Compensation
15.78M
35.61M
33.66M
41.27M
Change in Working Capital
-17.52M
6.69M
112k
10.44M
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
-9.81M
5.86M
-1.37M
-1.04M
Other Working Capital
-7.71M
836k
1.48M
11.48M
Other Non-Cash Items
25.01M
1.28M
349k
289k
CF from Investing Activities
12.94M
81.35M
100.43M
-132.63M
Investments in Property, Plant & Equipment
-5.3M
-3.65M
-5.5M
-40.66M
Net Acquisitions
0
0
0
0
Investment Purchases
-83.63M
0
-122.67M
-319.13M
Sales/Maturities of Investments
83.93M
85M
228.6M
227.16M
Other Investing Activites
17.94M
0
0
0
CF from Financing Activities
-75.47M
198.45M
26.48M
27.29M
Debt Repayment
-75.7M
0
0
0
Common Stock Issued
232k
188M
0
0
Common Stock Repurchased
0
0
0
-122k
Dividends Paid
0
0
0
0
Other Financing Activites
-75.47M
198.45M
26.48M
27.29M
Free Cash Flow
-155.45M
-148.77M
-133.15M
-151.1M
Operating Cash Flow
-150.14M
-145.12M
-127.65M
-110.44M
Capital Expenditures
-5.3M
-3.65M
-5.5M
-40.66M
Cash at Beginning of Period
227.58M
92.9M
93.63M
309.42M
Cash at End of Period
14.91M
227.58M
92.9M
93.63M
Net Change In Cash
-212.67M
134.68M
-732k
-215.79M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-677.02M
-480.47M
-312.74M
-150.08M
Net Income
-230.86M
-188.82M
-162.04M
-160.46M
Stock Repurchases
0
0
0
-122k
Dividend Paid
0
0
0
0
Retained Earnings
-856.68M
-677.02M
-480.47M
-312.74M
Other Distributions
-179.67M
-196.55M
-167.73M
-162.78M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
2.83M
86.63M
94.4M
103.48M
Annual Depreciation
6.25M
7.72M
5.69M
3M
Capital Expenditure
-5.3M
-3.65M
-5.5M
-40.66M
Net PPE
1.88M
82.55M
94.2M
141.15M
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
